S&P Futures
6,026.25 -12.00 (-0.20%) Dow Futures
44,904.00 -47.00 (-0.10%) Nasdaq Futures
20,910.50 -83.00 (-0.40%) Russell 2000 Futures
2,437.50 +5.10 (+0.21%) Crude Oil
69.15 +0.38 (+0.55%) Gold
2,674.20 +27.90 (+1.05%)
Intra-Cellular Therapies, Inc. (ITCI)
Pre-Market:
| Previous Close | 84.99 |
| Open | 85.32 |
| Bid | 86.24 x 100 |
| Ask | 86.65 x 100 |
| Day's Range | 84.72 - 86.60 |
| 52 Week Range | 58.78 - 93.45 |
| Volume | |
| Avg. Volume | 564,712 |
| Market Cap | 9.163B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | Feb 20, 2025 - Feb 24, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 101.87 |
GlobeNewswireIntra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: Evercore 7th Annual HealthCONx ConferenceTuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL Citi 2024 Global Health
- GlobeNewswire
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA BEDMINSTER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous sys
